Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Neoplasm Metastasis 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Metastatic Pancreatic Ductal Adenocarcinoma 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Unresectable Biliary Tract Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thromboembolism 1TNBC 1Sarcoma 1Peritoneal Neoplasms 1Oropharyngeal Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Mouth Neoplasms 1Locally Advanced or Metastatic Solid Tumours 1Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy 1Lip Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × TNBC × 130-nm albumin-bound paclitaxel × Clear all
NCT05918133 2025-03-11

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Biotheus Inc.

Phase 1/2 Active not recruiting
42 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡